Cited 0 times in Scipus Cited Count

Comparison of Short- and Long-Term Efficacy between Interleukin-17A and Interleukin-23 Inhibitors among Patients with Moderate-to-Severe Plaque Psoriasis: A Single Center Experience

DC Field Value Language
dc.contributor.authorHan, HJ-
dc.contributor.authorLee, H-
dc.contributor.authorKim, HS-
dc.contributor.authorJung, S-
dc.contributor.authorLee, ES-
dc.date.accessioned2024-01-23T23:44:08Z-
dc.date.available2024-01-23T23:44:08Z-
dc.date.issued2023-
dc.identifier.issn0494-4739-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/32148-
dc.description.abstractBackground: Interleukin (IL)-17 and IL-23 inhibitors have helped achieve clear skin in many patients with psoriasis. However, real-world data to compare short- and long-term efficacy of these biologies in Korean patients are lacking. Objective: To compare short- and long-term efficacy of IL-17A and IL-23 inhibitors in patients with moderate-to-severe psoriasis.Methods: We retrospectively evaluated efficacy of IL-17A and IL-23 inhibitors among patients treated at Ajou University Hospital from 2017 to 2022. The specific agents studied were as follows: secukinumab, 32 patients; ixekizumab, four patients; guselkumab, 13 patients; and risankizumab, 31 patients. Patients who were followed up for less than a year or changed biologies were excluded.Results: The rates of psoriasis area and severity index (PASI) 90 achievement of secukinumab were 62.5%, 86.7%, 89.3%, 80.8%, and 70.8% at weeks 16, 40, 88, 112, and 136, respectively. For ixekizumab, the PASI90 achievement rates were 75%, 100%, 75%, and 100% at weeks 16, 40, 64, and 88, respectively. The PASI90 achievement rates of guselkumab were 53.8%, 76.9%, 72.7%, and 77.8% at weeks 20, 44, 68, and 92, respectively. For risankizumab, PASI90 achievement rates were 69.7%, 90.0%, 93.7%, and 100% at weeks 28, 52, 76, and 100, respectively. Before 52 weeks, PASI90 achievement was significantly lower with guselkumab than with secukinumab (hazardratio=0.22). After 52 weeks, PASI90 achievement was significantly higher with risankizumab than with secukinumab (hazard ratio=2.00).Conclusion: PASI90 was achieved faster with IL-17A inhibitors than with IL-23 inhibitors. However, IL-23 inhibitors afforded the maintenance of a higher PASI score after 52 weeks.-
dc.language.isoko-
dc.titleComparison of Short- and Long-Term Efficacy between Interleukin-17A and Interleukin-23 Inhibitors among Patients with Moderate-to-Severe Plaque Psoriasis: A Single Center Experience-
dc.title.alternative중등도 및 중증 판상 건선에서 인터루킨-17 억제제와 인터루킨-23 억제제의 장단기 효과 비교: 단일 기관의 경험-
dc.typeArticle-
dc.subject.keywordGuselkumab-
dc.subject.keywordIxekizumab-
dc.subject.keywordPsoriasis-
dc.subject.keywordRisankizumab-
dc.subject.keywordSecukinumab-
dc.contributor.affiliatedAuthorLee, ES-
dc.type.localJournal Papers-
dc.citation.titleKorean journal of dermatology-
dc.citation.volume61-
dc.citation.number5-
dc.citation.date2023-
dc.citation.startPage275-
dc.citation.endPage282-
dc.identifier.bibliographicCitationKorean journal of dermatology, 61(5). : 275-282, 2023-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.relation.journalidJ004944739-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Dermatology
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse